Valeant Pharmaceuticals (VRX) reaches a revised agreement with Galderma which provides for a...


Valeant Pharmaceuticals (VRX) reaches a revised agreement with Galderma which provides for a resolution of all claims asserted in Galderma's pending litigation relating to Valeant's acquisition of Medicis Pharmaceutical MRX. Under the terms of the agreement, Galderma will continue to supply VRX with Restylane and Perlane, which it currently supplies to (MRX). In addition, VRX will make an upfront payment to Galderma on sales of Sculptra, and will obtain North American rights to Emervel, which is designed to provide correction of facial lines, contouring and volume loss or lip enhancement.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs